The five TNFα inhibitors showed similar efficacy profiles, although recent data show that adalimumab seems to be most effective in geriatric patients, while etanercept is associated with a lower risk of developing tuberculosis (Bonek et al., 2021). This evidence concerns the gene TNF and tuberculosis.